Ausgabe 4/2012
Inhalt (64 Artikel)
Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells
Coral O. Omene, Jing Wu, Krystyna Frenkel
The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis
Christopher M. Cabello, Sarah D. Lamore, Warner B. Bair III, Shuxi Qiao, Sara Azimian, Jessica L. Lesson, Georg T. Wondrak
Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells
Zahid M. Delwar, Dimitrios Avramidis, Elna Follin, Yan Hua, Åke Siden, Mabel Cruz, Kajsa M. Paulsson, Juan Sebastian Yakisich
Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest
Won Ki Kim, Ju-Hwa Kim, Kyungsil Yoon, Sunshin Kim, Jungsil Ro, Han Sung Kang, Sungpil Yoon
Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models
Angela Maria Di Francesco, Paolo Ubezio, Anna Rita Torella, Daniela Meco, Filomena Pierri, Giuseppe Barone, Gabriella Cusano, Claudio Pisano, Maurizio D’Incalci, Riccardo Riccardi
Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.
Mohammad Abolhassani, Adeline Guais, Edward Sanders, Frédéric Campion, Iduna Fichtner, Jacques Bonte, Gianfranco Baronzio, Giammaria Fiorentini, Maurice Israël, Laurent Schwartz
Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-Methylfunicone from Penicillium pinophilum and cisplatin
Elisabetta Buommino, Anna De Filippis, Rosario Nicoletti, Massimo Menegozzo, Simona Menegozzo, Maria Letizia Ciavatta, Antonietta Rizzo, Virginia Brancato, Maria Antonietta Tufano, Giovanna Donnarumma
Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks
Yu Kataoka, Toru Mukohara, Hideo Tomioka, Yohei Funakoshi, Naomi Kiyota, Yutaka Fujiwara, Masakazu Yashiro, Kosei Hirakawa, Midori Hirai, Hironobu Minami
Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia
Darya Habibi, Nadya Ogloff, Reza B. Jalili, Arla Yost, Andrew P. Weng, Aziz Ghahary, Christopher J. Ong
The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma
Juliana Romanini, Tânia R. Mielcke, Paulo C. Leal, Cláudia P. Figueiredo, João B. Calixto, Fernanda B. Morrone, Eraldo L. Batista Jr, Maria M. Campos
Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor
Lih-Ching Hsu, David E. Durrant, Ching-Chun Huang, Nai-Wen Chi, Riccardo Baruchello, Riccardo Rondanin, Cinzia Rullo, Paolo Marchetti, Giuseppina Grisolia, Daniele Simoni, Ray M. Lee
The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells
Ansgar Brüning, Petra Burger, Andrea Gingelmaier, Ioannis Mylonas
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors
Martin Schmidt-Hieber, Robert Dabrowski, Babette Aicher, Philipp Lohneis, Antonia Busse, Carola Tietze-Buerger, Birgit Reufi, Eckhard Thiel, Igor Wolfgang Blau
Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer
Jinah Park, Eunju Park, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Woo-Ho Kim, Do-Youn Oh, Yung-Jue Bang
Novel dichlorophenyl urea compounds inhibit proliferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis
James L. Figarola, Yehua Weng, Christopher Lincoln, David Horne, Samuel Rahbar
Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo
Juan R. Rodrigues, Jaime Charris, Rosa Ferrer, Neira Gamboa, Jorge Ángel, Bianca Nitzsche, Michael Hoepfner, Michael Lein, Klaus Jung, Claudia Abramjuk
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL
Jung Jin Hwang, Yong Sook Kim, Taelim Kim, Mi Joung Kim, In Gab Jeong, Je-Hwan Lee, Jene Choi, Sejin Jang, Seonggu Ro, Choung-Soo Kim
Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis
Ahmad Raza, Blake A. Jacobson, Adam Benoit, Manish R. Patel, Joe Jay-Dixon, Hiroshi Hiasa, David M. Ferguson, Robert Arthur Kratzke
Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells
Chin-Shiu Huang, Shih-Chieh Lyu, Miao-Lin Hu
Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines
Timothy C. Horan, Michael A. Zompa, Christopher T. Seto, Kyu Kwang Kim, Richard G. Moore, Thilo S. Lange
Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine (‘ecstasy’) through iterative chemical redesign: mechanisms and pathways to cell death
Agata M. Wasik, Michael N. Gandy, Matthew McIldowie, Michelle J. Holder, Anita Chamba, Anita Challa, Katie D. Lewis, Stephen P. Young, Dagmar Scheel-Toellner, Martin J. Dyer, Nicholas M. Barnes, Matthew J. Piggott, John Gordon
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines
Stefania Giudice, Luisa Benassi, Giorgia Bertazzoni, Eugenia Veratti, Daria Morini, Paola Azzoni, Maria P. Costi, Alberto Venturelli, Silvia Pirondi, Stefania Seidenari, Cristina Magnoni
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
Jens Samol, Malcolm Ranson, Edwina Scott, Euan Macpherson, James Carmichael, Anne Thomas, James Cassidy
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
Sang Joon Shin, Minkyu Jung, Hei-Cheul Jeung, Hye Ryun Kim, Sun Young Rha, Jae Kyung Roh, Hyun Cheol Chung, Joong Bae Ahn
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer
Taroh Satoh, Kensei Yamaguchi, Narikazu Boku, Wataru Okamoto, Tomotaka Shimamura, Kentaro Yamazaki, Xiaojin Shi, Hideyuki Mishima
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
Ron J. Keizer, Anthe S. Zandvliet, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer
Jean-Philippe Spano, Malcolm J. Moore, Yazdi K. Pithavala, Alejandro D. Ricart, Sinil Kim, Olivier Rixe
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma
Su Jin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Jongtae Lee, Dong-Seok Yim, Ho Yeong Lim
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
Yasushi Goto, Ikuo Sekine, Maki Tanioka, Takashi Shibata, Chiharu Tanai, Hajime Asahina, Hiroshi Nokihara, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Hironori Kikkawa, Emiko Ohki, Tomohide Tamura
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
Maarten J. Deenen, Heinz-Josef Klümpen, Dick J. Richel, Rolf W. Sparidans, Mariette J. Weterman, Jos H. Beijnen, Jan H. M. Schellens, Johanna W. Wilmink
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors
Elisabeth I. Heath, Karen Forman, Lisa Malburg, Shelby Gainer, A. Benjamin Suttle, Laurel Adams, Howard Ball, Patricia LoRusso
Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
Athanassios Argiris, Trevor M. Feinstein, Lin Wang, Tianbing Yang, Shruti Agrawal, Leonard J. Appleman, Ronald G. Stoller, Jennifer R. Grandis, Ann Marie Egloff
A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus
Kuai-le Zhao, Xi-chun Hu, Xiang-hua Wu, Xiao-long Fu, Min Fan, Guo-Liang Jiang
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy
Ramesh K. Ramanathan, Joe J. Stephenson, Glen J. Weiss, Linda A. Pestano, Ann Lowe, Alton Hiscox, Rafael A. Leos, Julie C. Martin, Lynn Kirkpatrick, Donald A. Richards
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
Andrew H. Ko, Hagop Youssoufian, Jayne Gurtler, Karel Dicke, Omar Kayaleh, Heinz-Josef Lenz, Mark Keaton, Terry Katz, Shaila Ballal, Eric K. Rowinsky
Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
Myoung Joo Kang, Yong Sang Hong, Kyu-pyo Kim, Sun Young Kim, Ji Yeon Baek, Min-Hee Ryu, Jae-Lyun Lee, Heung Moon Chang, Mi-Jung Kim, Hee Jin Chang, Yoon-Koo Kang, Tae Won Kim
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
Jason E. Faris, Jamie Arnott, Hui Zheng, David P. Ryan, Thomas A. Abrams, Lawrence S. Blaszkowsky, Jeffrey W. Clark, Peter C. Enzinger, Aram F. Hezel, Kimmie Ng, Brian M. Wolpin, Eunice L. Kwak
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
Ken Kato, Keisho Chin, Takaki Yoshikawa, Kensei Yamaguchi, Yasushi Tsuji, Taito Esaki, Kenji Sakai, Masami Kimura, Tetsuya Hamaguchi, Yasuhiro Shimada, Yasuhiro Matsumura, Ryuji Ikeda
Feasibility and effectiveness of inhaled carboplatin in NSCLC patients
Paul Zarogoulidis, Ellada Eleftheriadou, Iordanis Sapardanis, Vasiliki Zarogoulidou, Helliel Lithoxopoulou, Theodoros Kontakiotis, Nikolaos Karamanos, George Zachariadis, Maria Mabroudi, Athanasios Zisimopoulos, Kostantinos Zarogoulidis
Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil
Valerie Florin, Eve Desmedt, Sophie Vercambre-Darras, Laurent Mortier
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
Anthony B. El-Khoueiry, Cathryn J. Rankin, Edgar Ben-Josef, Heinz-Josef Lenz, Philip J. Gold, R. Darryl Hamilton, Rangaswamy Govindarajan, Cathy Eng, Charles D. Blanke
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer
Emma K. Beardsley, Sebastien J. Hotte, Scott North, Susan L. Ellard, Eric Winquist, Christian Kollmannsberger, Som D. Mukherjee, Kim N. Chi
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma
Wayne L. Furman, Lisa M. McGregor, M. Beth McCarville, Mihaela Onciu, Andrew M. Davidoff, Sandy Kovach, Dana Hawkins, Valerie McPherson, Peter J. Houghton, Catherine A. Billups, Jianrong Wu, Clinton F. Stewart, Victor M. Santana
Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer
Byung Woog Kang, Jong Gwang Kim, Yee Soo Chae, Yoo Jin Lee, Soo Jung Lee, Joon Ho Moon, Sang Kyun Sohn, Min Kyu Jung, Seong Woo Jeon, Yun-Jin Jang, Jongduk Seo, Yong Hyun Lee, Ohkyung Kwon, Ho Young Chung, Wansik Yu
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors
J. Paul Monk, Miguel Villalona-Calero, Joe Larkin, Greg Otterson, David S. Spriggs, Alison L. Hannah, Gillian F. Cropp, Robert G. Johnson, Martee L. Hensley
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction
David J. Adelstein, Cristina P. Rodriguez, Lisa A. Rybicki, Denise I. Ives, Thomas W. Rice
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer
Yasuhide Yamada, Tatsuro Yamaguchi, Hiroshi Matsumoto, Yasushi Ichikawa, Ayumu Goto, Ken Kato, Tetsuya Hamaguchi, Yasuhiro Shimada
Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis
Annie Brion, Faezeh Legrand, Fabrice Larosa, Françoise Schillinger, Francine Garnache-Ottou, Philippe Helias, Jean Fontan, Marian Heczko, Philippe Delaby, Etienne Daguindau, Jacqueline Vuillier, Adrien Chauchet, Eric Deconinck
Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure
Changhoon Yoo, Min-Hee Ryu, Baek-Yeol Ryoo, Mo Youl Beck, Heung-Moon Chang, Jae-Lyun Lee, Tae Won Kim, Yoon-Koo Kang
Synthesis and cytotoxic activities of some 2-Arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines
Yakini Brandy, Innocent Ononiwu, Dolapo Adedeji, Vonetta Williams, Claudia Mouamba, Yasmine Kanaan, Robert L. Copeland Jr, Dwayne A. Wright, Ray J. Butcher, Samuel R. Denmeade, Oladapo Bakare
Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes
Joanna Edyta Fraczek, Mathieu Vinken, Dirk Tourwé, Tamara Vanhaecke, Vera Rogiers
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study
Veronica Marchetti, Mario Giorgi, Anna Fioravanti, Riccardo Finotello, Simonetta Citi, Bastianina Canu, Paola Orlandi, Teresa Di Desidero, Romano Danesi, Guido Bocci
Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells
Erika Rimondi, Maria Grazia di Iasio, Arianna Gonelli, Claudio Celeghini, Paola Secchiero, Giorgio Zauli
Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells
David Davidson, Jeremy Grenier, Veronica Martinez-Marignac, Lilian Amrein, May Shawi, Marc Tokars, Raquel Aloyz, Lawrence Panasci
Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model
Felix Kratz, Iduna Fichtner, Ralph Graeser
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay
Sarah Schott, Markus Wallwiener, Beate Kootz, Harald Seeger, Tanja Fehm, Hans Neubauer
Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients
Olivier Mir, Jérôme Alexandre, Romain Coriat, Stanislas Ropert, Pascaline Boudou-Rouquette, Thach Bui, Jeanne Chapron, Jean-Philippe Durand, Daniel Dusser, François Goldwasser
Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples
Maria Grazia di Iasio, Riccardo Addobbati, Oriano Radillo, Rebecca Voltan
Reversible posterior leukoencephalopathy syndrome and trastuzumab
Hiroyasu Kaneda, Isamu Okamoto, Taroh Satoh, Kazuhiko Nakagawa
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma
Hee Kyung Ahn, Soohyeon Lee, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis
Yevgeniy Balagula, Shenhong Wu, Xiao Su, Darren R. Feldman, Mario E. Lacouture
Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies
Caroline Peyrode, Valérie Weber, Emmanuelle David, Aurélien Vidal, Philippe Auzeloux, Yves Communal, Marie Mélanie Dauplat, Sophie Besse, François Gouin, Dominique Heymann, Jean Michel Chezal, François Rédini, Elisabeth Miot-Noirault
Antiangiogenic treatments and mechanisms of action in renal cell carcinoma
Sylvie Négrier, Eric Raymond
Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC)
George R. Blumenschein Jr